H. Lundbeck A/S- (HLUYY) Upgraded by Zacks Investment Research to Hold
Zacks Investment Research upgraded shares of H. Lundbeck A/S- (OTCMKTS:HLUYY) from a sell rating to a hold rating in a report released on Wednesday.
According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. Its products are targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, epilepsies, Alzheimer’s and Parkinson’s diseases. The Company is involved in the development of new and improved drugs for the treatment of psychiatric and neurological disorders. H. Lundbeck A/S is headquartered in Copenhagen, Denmark. “
Shares of H. Lundbeck A/S- stock opened at $60.05 on Wednesday. H. Lundbeck A/S- has a 1 year low of $46.61 and a 1 year high of $73.90. The company has a current ratio of 1.31, a quick ratio of 1.06 and a debt-to-equity ratio of 0.01. The firm has a market cap of $12.29 billion, a price-to-earnings ratio of 23.92, a price-to-earnings-growth ratio of 2.24 and a beta of -0.23.
H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Denmark and internationally. Its products include Abilify Maintena, Brintellix/Trintellix, Cipralex/Lexapro, Northera, Onfi, Rexulti, Sabril, and Xenazine.
Featured Story: Trading Strategy Methods for Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with MarketBeat.com's FREE daily email newsletter.